Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accumulated Expenses: 2023-2025

Historic Accumulated Expenses for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to $7.0 million.

  • Artiva Biotherapeutics' Accumulated Expenses fell 15.80% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 15.80%. This contributed to the annual value of $7.4 million for FY2024, which is 7.80% down from last year.
  • As of Q3 2025, Artiva Biotherapeutics' Accumulated Expenses stood at $7.0 million, which was up 20.35% from $5.8 million recorded in Q2 2025.
  • Artiva Biotherapeutics' Accumulated Expenses' 5-year high stood at $8.3 million during Q3 2024, with a 5-year trough of $5.8 million in Q2 2025.
  • In the last 3 years, Artiva Biotherapeutics' Accumulated Expenses had a median value of $7.0 million in 2025 and averaged $7.0 million.
  • Data for Artiva Biotherapeutics' Accumulated Expenses shows a maximum YoY fell of 15.80% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Artiva Biotherapeutics' Accumulated Expenses stood at $8.0 million in 2023, then decreased by 7.80% to $7.4 million in 2024, then fell by 15.80% to $7.0 million in 2025.
  • Its Accumulated Expenses was $7.0 million in Q3 2025, compared to $5.8 million in Q2 2025 and $6.4 million in Q1 2025.